我们的管线

在研治疗方案

我们研发团队的工作目标就是准确定位脑部疾病的发病机制。我们通力合作,致力于研发出重新定义患者治疗标准的创新治疗方案,满足最亟待满足的治疗需求。
项目 适应症 I期临床试验 II期临床试验 III期临床试验 上市申请
Eptinezumab (anti-CGRP mAb) Migraine prevention Filing

更多操作

Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.

Eptinezumab (anti-CGRP mAb) Episodic cluster headache 3

更多操作

Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.

Brexpiprazole* Agitation in Alzheimer's disease 3

更多操作

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Brexpiprazole* PTSD 3

更多操作

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonergic, dopaminergic, and especially the noradrenergic systems are believed to be involved in PTSD symptomatology with re-experiencing, Negative cognition and mood, Avoidance and Arousal.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Brexpiprazole* Borderline Personality DIsorder 2

更多操作

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. Serotonergic and Dopaminergic stabilization may directly address the pathways implicated in the BPD features of impulse aggression (SER), and emotional dysregulation, impulsivity, and cognitive disturbances (DA).

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Aripiprazole 2-month injectable* Schizophrenia + Bipolar I Disorder 1

更多操作

Aripiprazole is a small molecule. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and antagonist at serotonin 5-HT2A receptors. A 2-month formulation will serve as a treatment option when treating patients with Schizophrenia or Bipolar I disorder where long-acting treatment is needed.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Lu AG06466 (MAGL inhibitor)* PTSD 1

更多操作

Lu AG06466 is a small molecule expected to be highly brain-penetrant. Lu AG06466 is a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing the actions of 2-AG may produce beneficial effects across a range of symptoms including stress, anxiety and hyperarousal; symptoms which are relevant to PTSD.

*MAGL: Monoacylglycerol lipase. PTSD study has been initiated, additional phase 1b studies within psychiatry/neurology will be explored during 2021.

Lu AG06479 (MAGL inhibitor)* Neurology, Psychiatry 1

更多操作

Lu AG06479 is a small molecule expected to be highly brain-penetrant. Lu AG06466 is a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing 2-AG levels is a viable approach to restore brain homeostasis.

*MAGL: Monoacylglycerol lipase. PTSD study has been initiated, additional phase 1b studies within psychiatry/neurology will be explored during 2021.

Lu AF82422 (alpha-synuclein mAb) Synucleinopathies 1

更多操作

Lu AF82422 is a monoclonal antibody targeting alpha-synuclein. Misfolding, aggregation and extracellular spreading of alpha-synuclein is believed to play a major role in disease pathology and progression in Parkinson’s disease and other neurodegenerative disorders.

Lu AF28996 (D1 D2 agonist) Parkinson's disease 1

更多操作

Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients.

Lu AG09222 (PACAP mAb)* Migraine 1

更多操作

LU AG09222 is a monoclonal antibody designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP) signaling for migraine prevention. PACAP has emerged as a signaling molecule in the pathophysiology of migraine.

*PACAP: Pituitary adenylate cyclase-activating polypeptide

Lu AF87908 (Tau mAb) Tauopathies 1

更多操作

Lu AF87908 (Tau mAb) is a monoclonal antibody targeting the pathological form of the protein tau which is believed to play a pivotal role in the development and progression of Alzheimer’s disease and other neurodegenerative disorders.

更多信息

研究与开发

研究和开发创新治疗方案是我们的核心所在。

患者

我们将患者视为和你我一样的普通人,并且致力于帮助和支持他们。

科研合作

成功的经验和科研传统为我们提供了强大的全球资源网络体系。